# Panaceo "MED" for IBS (Irritable Bowel Syndrome)

> **NCT03817645** · NA · COMPLETED · sponsor: **Scigenia GmbH** · enrollment: 41 (actual)

## Conditions studied

- Irritable Bowel Syndrome
- Microbial Colonization
- Intestinal Disease

## Interventions

- **OTHER:** Zeolite

## Key facts

- **NCT ID:** NCT03817645
- **Lead sponsor:** Scigenia GmbH
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-09
- **Primary completion:** 2019-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03817645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03817645, "Panaceo "MED" for IBS (Irritable Bowel Syndrome)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03817645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*